MDR1 gene polymorphism in allogenic kidney transplant patients with tremor

Pharmacological Reports

Volumn 57, Issue 2, 2005, Pages 241-245

  Kotrych, Katarzyna ^a   Domański, Leszek ^a   Górnik, Wanda ^a   Droździk, Marek ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Kidney transplant; MDR1 gene; P glycoprotein; Polymorphism; Tremor

Indexed keywords

CYCLOSPORIN A; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; MEMBRANE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; XENOBIOTIC AGENT;

ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG ACCUMULATION; DRUG TRANSPORT; ENDOTHELIUM CELL; FEMALE; GENOTYPE; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEMBRANE TRANSPORT; NEUROTOXICITY; POSTOPERATIVE PERIOD; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECIPIENT; STATISTICAL SIGNIFICANCE; TREMOR;

EID: 20344398427     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Bechstein WO: Neurotoxicity of calcineurin inhibitors: impact and clinical managment. Transpl Int, 2000, 13, 313-326.
2. Drozdzik M, Białecka M. Myśliwiec K, Honczarenko K, Stankiewicz J, Sych Z: Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics, 2003, 13, 259-263.
3. Gijtenbeek JMM, van den Bent MJ, Vecht ChJ: Cyclosporine neurotoxicity: a review. J Neurol, 1999, 246, 339-346.
4. Gustincich S, Manfiolett G, Del Sal G, Schneider C, Carnici P: A fast method for high-quality genomic DNA extraction from human nucleated cells. Biotechniques, 1991, 11, 289-301.
5. Hoffmeyer S, Burk O, Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA, 2000, 97, 3473-3478.
6. Kochi S, Takanaga H, Matsuo H, Naito M, Tsuruo T, Sawada Y: Effect of cyclosporin A or tacrolimus on the function of blood-brain barrier cells. Eur J Pharmacol, 1999, 372, 287-295.
7. Lankas GR, Cartwright ME, Umbenhauer D: P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol Appl Pharmacol, 1997, 143, 357-365.
8. Lo A, Burcart GJ: P-glycoprotein and drug therapy in organ transplantation. J Clin Pharmacol, 1999, 39, 995-1005.
9. Schinkel AH, Smit J, Tellingen O, Beijnen J, Wagenaar E, van Deemetr L: Disruption of the mouse MDR1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell, 1994, 77, 491-502.
10. Schinkel AH, Wagenaar E, Deemter L, Mol C, Borst P: Absence of the MDR1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest, 1995, 96, 1698-1705.
11. Schinkel AH, Wagenaar E, Mol CA, Deemter L: P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest, 1996, 97, 2517-1524.
12. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahasi M et al.: Expression of P-glycoprotein in human. J Pharmacol Exp Ther, 2001, 297, 1137-1143.
13. Tsuji A: P-glycoprptein-mediated efflux transport of anticancer drugs at the blood-brain barrier. Ther Drug Monit, 1998, 20, 588-590.
14. Yamauchi A, Ieiri I, Kataoka Y, Tanabe M, Nishizaki T, Oishi R, Higuchi S et al.: Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation, 2002, 74, 571-573.